Related Experiment Video
Updated: Aug 5, 2026

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration
Published on: May 31, 2018
Ribose cysteine protects against acetaminophen-induced hepatic and renal toxicity
A M Lucas1, G Hennig, P K Dominick
1Department of Pharmaceutical Sciences, University of Connecticut, Storrs 06269-2092, USA.
Ribose cysteine (RibCys) protects against acetaminophen (APAP)-induced kidney damage. This cysteine prodrug reduced APAP toxicity and covalent binding in both liver and kidney tissues.
Area of Science:
- Toxicology
- Pharmacology
- Biochemistry
Background:
- Acetaminophen (APAP) overdose causes severe liver and kidney damage.
- Ribose cysteine (RibCys) is a cysteine prodrug known to protect against APAP-induced liver toxicity by increasing glutathione levels.
- The potential of RibCys to protect against APAP-induced kidney injury remains to be fully elucidated.
Purpose of the Study:
- To investigate the efficacy of RibCys in preventing acetaminophen-induced kidney damage in a murine model.
- To assess the impact of RibCys on APAP covalent binding to proteins in both hepatic and renal tissues.
Main Methods:
- Mice were administered APAP alone or in combination with RibCys.
- Liver and kidney toxicity were evaluated using plasma sorbitol dehydrogenase (SDH) and blood urea nitrogen (BUN) levels, respectively.
- Histopathological examination and assessment of APAP covalent binding to proteins were performed.
Main Results:
- APAP treatment led to significant elevations in SDH and BUN, indicating severe liver and kidney damage.
- Co-administration of RibCys with APAP normalized SDH and BUN levels, comparable to control groups.
- Histopathology confirmed the absence of hepatic and renal necrosis in RibCys-treated mice.
- RibCys cotreatment significantly decreased APAP covalent binding to hepatic and renal proteins.
Conclusions:
- Ribose cysteine effectively protects against both acetaminophen-induced liver and kidney toxicity.
- RibCys mitigates APAP-induced nephrotoxicity by reducing covalent binding of APAP metabolites to cellular proteins.
- This cysteine prodrug demonstrates significant therapeutic potential for preventing APAP-induced organ damage.
More Related Videos
07:16Resin-Assisted Capture Coupled with Isobaric Tandem Mass Tag Labeling for Multiplexed Quantification of Protein Thiol Oxidation
Published on: June 21, 2021
08:32A Pre-Clinical Model of Synovitis Using Ex vivo Human Synovial Tissue with Preserved Function and Architecture
Published on: March 20, 2026
Related Concept Videos
RNA Editing
Acetals and Thioacetals as Protecting Groups for Aldehydes and Ketones
In the presence of multiple functional groups, when selective reduction of one group over the other is desired, groups like aldehydes and ketones that form acetals...
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Phase II Reactions: Acetylation Reactions
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase